ICCM Icecure Medical
Company Analysis
Latest News
🟢 Icecure Medical is trading 6% up today after China approved ProSense for commercialization
Icecure Medical is trading at $2.27 (+6.07%) after receiving China NMPA Class III approval for its ProSense cryoablation system and associated cryoprobes. -...
IceCure Medical Secures China Approval for ProSense Tumor-Freezing System
IceCure Medical Ltd. received regulatory approval from China’s National Medical Products Administration (NMPA) for its ProSense cryoablation system. The NMPA...
🟢 Icecure Medical is trading 6.3% up in pre-market — catalyst remains unconfirmed
Icecure Medical is trading 6.32% up at $2.24 after rising from the September 9 close of $2.11; the catalyst remains unconfirmed. - No reliable September 10,...
🔴 Icecure Medical is trading 7.89% down in pre-market
Icecure Medical is trading 7.89% down at $2.10, with no identifiable company-specific announcement on September 2, 2026. - Latest earnings-related news,...
🔴 Icecure Medical is trading 8.1% down today, extending its recent seven-session decline
Icecure Medical is trading 8.1% down at $2.23, with no clear company-specific catalyst confirmed for August 24, 2026. - The recent seven-session decline took...
🔴 Icecure Medical is trading 10% down in pre-market — no company-specific catalyst confirmed
Icecure Medical is trading 10.32% down at $2.18, with no direct company-specific catalyst confirmed for August 24, 2026. - The decline extends a seven-session...
🔴 Icecure Medical is trading 7% down in pre-market with no direct catalyst confirmed
Icecure Medical is trading at $2.26 (-7%) after several weaker sessions amid a modestly cautious market, with no direct catalyst confirmed. - No new negative...
🔴 Icecure Medical is trading 6% down today amid caution after quarterly earnings miss
Icecure Medical is trading 5.95% down at $2.37, with continued caution after the August 12 quarterly earnings miss contributing to the decline. - Losses...
🟢 Icecure Medical is trading 7.7% up in after-hours trading after positive cancer-vaccine trial news
Icecure Medical is trading at $2.80 (+7.69%) as positive cancer-vaccine trial news lifted healthcare-sector sentiment. - The move appears primarily...
🟢 Icecure Medical is trading 7.7% up today on healthcare-sector strength after positive cancer-vaccine trial news
Icecure Medical is trading 7.69% up at $2.80, mainly reflecting healthcare-sector strength following positive cancer-vaccine trial news. - It closed at $2.60...
🟢 Icecure Medical is trading 5.8% up in pre-market as catalyst remains unclear
Icecure Medical is trading 5.8% up at $2.75 after closing at $2.60 on August 18, 2026, with no fresh company-specific announcement identified to explain the...
🟢 Icecure Medical is trading 6.92% up in after-hours trading with no fresh announcement explaining rebound
Icecure Medical is trading 6.92% up at $2.78 in after-hours trading, with no fresh announcement explaining the rebound. - It closed at $2.60 on August 18,...
🔴 Icecure Medical is trading 6% down today after wider-than-expected Q2 losses
Icecure Medical is trading 6.03% down at $2.65 as U.S. stocks decline broadly, with sentiment pressured by last week’s Q2 revenue miss and wider-than-expected...
IceCure Medical Validates ProSense Tech, Citing New U.S. Breast Cancer Studies
IceCure Medical highlighted two new peer-reviewed U.S. studies on August 17, 2026. These publications provide clinical validation for the company’s ProSense®...
🟢 Icecure Medical is trading 6.03% up in after-hours trading
Icecure Medical is trading 6.03% up at $2.99 after closing at $2.82 on August 17, 2026, with no clear company-specific announcement explaining the after-hours...
🔴 Icecure Medical is trading 5.63% down today — no clear company-specific announcement explains decline
Icecure Medical is trading 5.63% down at $2.85, with no clear new company-specific announcement directly explaining the August 17, 2026 decline. - Recent...
IceCure Medical Secures Armistice Capital Stake Following 45% Revenue Growth
Armistice Capital, LLC disclosed a 9.99% beneficial ownership stake in IceCure Medical in a Schedule 13G filing on August 14, 2026. The investment firm now...
🔴 Icecure Medical is trading 6.9% down in after-hours trading after Q2 revenue missed analyst expectations
Icecure Medical is trading 6.9% down at $2.79 after investors continued selling following the August 12, 2026, second-quarter earnings release, which reported...
🔴 Icecure Medical is trading 6.28% down today after Q2 revenue missed analyst expectations
Icecure Medical is trading at $2.91, down -6.28%, after second-quarter revenue missed analyst expectations despite strong year-over-year growth. - Selling...
🔴 Icecure Medical is trading 13% down today after Q2 EPS and revenue missed estimates
Icecure Medical is trading 13.01% down now at $3.05 after Q2 results missed expectations. - Q2 EPS was -$3.11 versus a -$1.53 estimate; revenue reached...